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Abstract 
Purpose: The objectives of this review are to summarize the current practices and major recent advances in critical 
care nutrition and metabolism, review common beliefs that have been contradicted by recent trials, highlight key 
remaining areas of uncertainty, and suggest recommendations for the top 10 studies/trials to be done in the next 
10 years.
Methods: Recent literature was reviewed and developments and knowledge gaps were summarized. The panel 
identified candidate topics for future trials in critical care nutrition and metabolism. Then, members of the panel rated 
each one of the topics using a grading system (0–4). Potential studies were ranked on the basis of average score.
Results: Recent randomized controlled trials (RCTs) have challenged several concepts, including the notion that 
energy expenditure must be met universally in all critically ill patients during the acute phase of critical illness, the 
routine monitoring of gastric residual volume, and the value of immune‑modulating nutrition. The optimal protein 
dose combined with standardized active and passive mobilization during the acute phase and post‑acute phase of 
critical illness were the top ranked studies for the next 10 years. Nutritional assessment, nutritional strategies in criti‑
cally obese patients, and the effects of continuous versus intermittent enteral nutrition were also among the highest‑
ranking studies.
Conclusions: Priorities for clinical research in the field of nutritional management of critically ill patients were sug‑
gested, with the prospect that different nutritional interventions targeted to the appropriate patient population will 
be examined for their effect on facilitating recovery and improving survival in adequately powered and properly 
designed studies, probably in conjunction with physical activity.
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Introduction
The last decade has seen much needed increases in the 
number of methodologically sound studies in the field 
of nutrition therapy of the critically ill, adding to the 
expanding body of knowledge and highlighting or induc-
ing many uncertainties and controversies [1]. In this 
review of the research agenda for intensive care medicine 
nutrition and metabolism in adults, we summarize the 
current practices, major recent advances in the field, and 
common beliefs that have been contradicted by recent 
trials. We then highlight key remaining areas of uncer-
tainty and suggest recommendations for the top 10 stud-
ies/trials to be done in the next 10 years.
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Current standard of care
Recent randomized clinical trials have questioned sev-
eral previously accepted but poorly supported concepts 
in nutrition therapy of critically ill patients. Based on 
the current available evidence, defining a universally 
accepted standard of care is difficult. Existing clinical 
practice guidelines by different societies/organizations 
have provided detailed evidence-based assessment of 
available evidence. Although the resulting recommenda-
tions have similarities, significant differences exist that 
reflect lower levels of evidence and differences in the 
methodology of guideline development [2]. In practice, 
considerable variations also exist. The use of routes of 
nutrition [enteral nutrition (EN) or parenteral nutrition 
(PN)] and the dose of calories and protein all vary across 
centers and countries (Supplemental References). For 
the evaluation of energy expenditure (EE), different pre-
dictive equations are used. Indirect calorimetry is infre-
quently used, reflecting the limited supportive evidence, 
the limited availability, and the difficulties in performing 
and interpreting the measurement in critically ill patients 
(Fig. 1) [3, 4].
Major recent advances and common beliefs 
that have been contradicted by recent trials
Provision of early EN and PN
The value of early initiation of EN is supported by physi-
ologic data. Over the first week of ICU admission, most 
critically ill patients experience the non-nutritional ben-
efits of EN by virtue of the gastrointestinal responses 
[maintaining gut integrity, supporting the diversity of 
the microbiome, and sustaining gut-associated lym-
phoid tissue (GALT) and secretory IgA production], 
immune responses [sustaining mucosa-associated lym-
phoid tissue  (MALT) at distant sites, stimulating Th2 
anti-inflammatory lymphocytes and T-regulatory cells], 
and metabolic responses [increasing incretin release, and 
reducing generation of advanced glycation end products 
(AGEs)] (Supplementary References). Meta-analyses of 
randomized controlled trials (RCTs) demonstrate that 
early EN is associated with reduction in mortality and 
infections compared to withholding early EN, although 
the included individual clinical trials are heterogeneous 
and not adequately powered [5]. Additionally, the defini-
tion of early nutrition remains arbitrary and has ranged 
from 3 to 7 days in different interventional studies. Nev-
ertheless, the notion that EE must be met universally in 
all ICU patients during the acute phase of critical illness 
has been challenged. Indeed, a number of trials in gen-
eral ICU patients and in selected populations (acute res-
piratory failure, acute lung injury, refeeding syndrome) 
show that restricted feeding strategies described as 
“permissive or trophic” during the early phase of critical 
illness result in similar outcomes compared with stand-
ard caloric intake (Table 1) [6–10]. However, “standard” 
caloric intake in these trials met only 70–80% of EE. The 
protein intakes also differed between the study arms in 
most studies [6, 7], but not all [8]. So it remains uncertain 
whether the provision of energy to fully match EE has 
clinical benefit.
Along with the lack of benefit of early aggressive EN, 
the use of supplemental PN in the first week to achieve 
caloric targets for all patients has now been challenged. 
The EPaNIC study, conducted in critically ill adults in 
whom caloric targets could not be met by EN alone, 
showed that late initiation of PN (i.e., after a week of 
critical illness) was associated with faster recovery and 
fewer complications, as compared with early initiation 
[11]. Interestingly, the similarly designed PEPaNIC trial 
in critically ill children showed similar results [12]. The 
Early PN trial found that early PN (i.e., within the first 
hours of admission in ICU) to critically ill adults with 
relative contraindications to early EN was not associ-
ated with a significant clinical benefit [13]. Another 
study enrolled patients who received less than 60% of 
EE from EN at ICU day 3 and found that supplemen-
tal PN was associated with a decrease of late infections 
compared to EN alone [14]. Of note, common infec-
tions, including pneumonia and bloodstream infec-
tions, did not decrease [14]. While these studies are 
somewhat conflicting, it would appear that there is no 
benefit in providing nutrition parenterally early in the 
ICU stay.
The underlying mechanisms and potential conse-
quences of an increased provision of nutrients during the 
early phase of critical illness are currently investigated. A 
pre-planned secondary analysis of 600 patients included 
in the EPaNIC trial, with prospective assessment of 
functional weakness, revealed that tolerating a substan-
tial macronutrient deficit during the first week of criti-
cal illness reduced ICU-acquired weakness (ICU-AW). 
In addition, muscle biopsies indicated that activation of 
autophagy might explain the protective effect on weak-
ness of delaying PN delivery [15]. Hyperglycemia during 
feeding may occur since the endogenous production of 
glucose cannot be fully inhibited by exogenous caloric 
supply [3]. Nutrient delivery may lead to the develop-
ment of refeeding syndrome or may counteract poten-
tially adaptive early anorectic response of severe illness, 
particularly in severely ill patients, identified by high 
“nutritional risk” as discussed below. Irrespective of the 
underlying mechanisms, the optimal amount of calories 






“Calculate energy and 
protein requirement”
“Take steps to improve 
tolerance to gastric feeding”
“Implement enteral 
feeding protocol”
“Do not use gastric residual volumes as 
part of routine care”
“Start PN when EN is not feasible or 
sufficient in high-risk patients”
• How to identify patients at highest nutritional risk?
• What is the role of the existing nutritional risk scores?
• Does nutrition guided by measuring EE affect patient outcome?
• What is the approach for estimating EE that is associated with improved 
outcome?
• What is the optimal calorie dose?
• What is the optimal protein dose?
• What is the role of novel pro-motility agents?
• Which patients benefit from post-pyloric feeding tube placement?
• What is the optimal timing for initiation of artificial feeding?
• What is the optimal strategy for managing EN?
• Does gastric residual monitoring have a role in the identification of patients 
with gastrointestinal dysfunction?
• What is the role of pro-motility agents?
• Does improving gastric emptying result in improved clinical outcomes?
• What is the optimal timing of initiating PN?
• What is the optimal caloric dose of PN?
• What is the optimal composition of PN? Lipids? Micronutrients?
• Who is at “high risk”? Does it mean more risk of harm by underfeeding or 
more risk of harm by EN/PN???
Fig. 1 Flowchart highlighting some of the uncertainties in the nutritional support decision‑making. The boxes on the left are based on the “bundle 
statements” from the Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN) Guidelines for the 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The CALORIES trial was a pragmatic RCT that com-
pared early EN to early PN for the first 5 days in an unse-
lected critically ill population. The majority of patients 
in both arms did not reach EE targets and no difference 
on short-term outcome was found [16]. A recent meta-
analysis that included the results of the CALORIES trial 
comparing EN to PN found no effect on overall mortal-
ity [17]. However, EN was associated with lower infective 
complications and shorter ICU length of stay (LOS) [17].
Nutritional risk assessment
It has been generally accepted that a small percent-
age of patients, those at highest nutritional risk, may 
require the nutritional benefits of therapy where full 
macro- and micronutrient provision maximizes protein 
synthesis, supports lean body mass, and corrects nutri-
ent deficiencies. Hence, there has been increasing work 
to define nutritional risk assessment in nutrition therapy 
[18]. The NUTRIC (The Nutrition Risk in Critically ill) 
score was proposed to identify those who will benefit 
the most from nutrition therapy or be harmed the most 
by ongoing inattention to nutrition. The clinical utility 
of this score has been examined in three multi-institu-
tional databases. These studies demonstrate that patients 
with high NUTRIC scores have reduced mortality with 
increased nutrition intake compared to patients with 
low NUTRIC scores where no such relationship between 
intake and mortality exists [18, 19]. Of note, the variables 
included in this score mainly reflect the severity of dis-
ease and are not direct measures of nutritional status. A 
post hoc analysis of the PermiT trial showed that per-
missive underfeeding was associated with similar mor-
tality compared with standard feeding in patients with 
high and low nutritional risk as assessed by the NUTRIC 
score and several other nutritional risk tools [20]. Other 
scores have also been developed, such as the Nutrition 
Risk Screening-2002 (NRS-2002) score and the Patient- 
And Nutrition-Derived Outcome Risk Assessment Score 
(PANDORA); the latter has yet to be validated in the 
critically ill population [21, 22]. The role of nutritional 
assessment using an objective measurement of body 
composition or more specifically muscle mass (using 
CT, ultrasound, or bioelectric impedance) requires fur-
ther study (Supplementary References). Although these 
parameters identify increased risk of death, it is unclear 
if these are modifiable by nutrition or if they just reflect 
disease severity.
The uncertainty about the optimal approach for 
nutritional assessment is further complicated by the 
controversy regarding whether patients with severe 
undernutrition would benefit or alternatively suffer 

























































































































































































































































































































































































































































































































































































































hypophosphatemia within 72  h of initiation of nutri-
tion, restricted versus standard caloric intake resulted 
in no difference in the primary endpoint of the number 
of days alive after ICU discharge, but with more patients 
alive at day 60 [23]. Post hoc analysis of the PermiT trial 
suggested that patients with low prealbumin levels might 
have better outcomes with restricted calories [20]. Post 
hoc analysis of the EPaNIC trial showed that the benefi-
cial effect of a delay in the initiation of PN was general-
ized across different strata of severity of illness including 
those who were most severely ill [24]. Interestingly, the 
PEPaNIC trial showed that early PN provoked more 
harm in children at increased nutritional risk according 
to their Screening Tool for Risk on Nutritional Status and 
Growth (STRONGkids) score [12].
Another aspect of nutritional assessment is how to dif-
ferentiate the acute (catabolic) phase and the post-acute 
(anabolic) phase. There is a need for a dynamic marker to 
identify patients “readiness for enhanced feeding”. Such a 
marker would allow an adaptation of the nutritional strat-
egy to the clinical evolution based on endocrinological or 
metabolic signals rather than starting enhanced energy/
protein intake at a predefined number of days.
Gastric residual volume (GRV)
The role of GRV measurement to monitor tolerance of 
patients on EN has been challenged. Although GRVs are 
generally considered to indicate gastric emptying rate, 
volumes aspirated are also affected by the rate of feed 
administration, the technique of aspiration, gastric secre-
tion, and duodeno-gastric reflux. Increasing the limit of 
monitored GRV from 200 to 500  ml (REGANE study) 
or adopting a no routine monitoring of GRV strategy 
(NUTRIREA1 study) among adults requiring mechani-
cal ventilation did not increase pneumonia [25, 26]. 
However, these studies included predominately patients 
admitted for medical (as opposed to surgical) reasons and 
were underpowered to assess the impact on other clinical 
outcomes. In one study, a 24-h total GRV of greater than 
250 ml was shown to predict slow gastric emptying, but 
the sensitivity and negative predictive value were modest 
[27].
Immune‑modulating nutrition
The use of immune-modulating macronutrients (e.g., 
glutamine, arginine, and omega-3 fatty acids) and micro-
nutrients (e.g., antioxidant vitamins A, C, and E and the 
minerals selenium and zinc) used alone (pharmaconutri-
tion) or in combination (immunonutrition) to enrich EN 
or PN and improve outcomes of ICU patients has been 
challenged in a number of RCTs [28]. The REDOXS trial 
showed an increase in mortality with high doses of enteral 
and parenteral glutamine (0.6  g/kg per day) [29]. The 
OMEGA trial showed that enteral supplementation of n-3 
fatty acids, γ-linolenic acid, and antioxidants in patients 
with acute lung injury did not improve the primary end-
point of ventilator-free days or other clinical outcomes 
and might be harmful [30]. In the MetaPlus study, high-
protein EN enriched with glutamine, omega-3 fatty acids, 
selenium, and antioxidants did not reduce infectious com-
plications or improve other clinical endpoints when com-
pared to standard high-protein EN and may have been 
harmful as suggested by an increased adjusted 6-month 
mortality [31]. A recent meta-analysis showed that enteral 
glutamine supplementation does not confer clinical ben-
efit in critically ill patients [32]. However, in severe burn 
patients, enteral glutamine supplementation was associ-
ated with reduction in hospital mortality and stay [32].
The danger of providing arginine in the setting of sepsis 
has been challenged, as multiple studies in septic patients 
showed no adverse hemodynamic changes in response to 
intravenous arginine infusion [33]. The use of arginine/
fish oil formulas may still be beneficial in elective sur-
gical patients, as its use has been shown in four recent 
meta-analyses to reduce infection and hospital LOS and 
improve other clinical outcomes (Supplementary Refer-
ences). In severe acute pancreatitis, three small studies 
in immune-modulating nutrition of varying components 
showed improved outcomes, but the small numbers 
enrolled were such that only one reached significance 
and a meta-analysis was negative (Supplementary Ref-
erences). This last group of patients (severe acute pan-
creatitis) should be studied further before discounting 
immune-modulating nutrition across the board. Impor-
tant questions regarding immune-modulating nutrition 
remain (Table 1).
Glucose control
The survival benefit of tight glucose control (TGC) (tar-
get 4.4–6.1  mmol/L) observed in an RCT of predomi-
nantly (cardiac) surgical patients and an RCT of medical 
ICU patients [34, 35] could not be reproduced in other 
RCTs [36]. The largest trial, NICE-SUGAR, showed 
increased 90-day mortality with TGC compared to a tar-
get of less than 10 mmol/L [37]. The observed differences 
in outcome may be related to different targets achieved, 
different blood glucose analyzing methodology, or the 
difference in the amount and route of early nutritional 
intake between the Leuven as compared to the other 
trials [36, 38]. After 15  years of intense research in this 
field, a few assertions are widely accepted: (1) there are 
three domains of dysglycemia (severe hyperglycemia, 
moderate hypoglycemia, and high glycemic variability) 
which are individually and synergistically associated with 
poor vital outcome; (2) blood glucose control is demand-
ing, difficult to perform, and requires technological 
improvements in monitoring and therapeutic modalities 
including automated algorithms and new agents such as 
long-acting insulin or glucagon-like peptide-1 (GLP-1) 
agonists; (3) the optimal target could differ over time and 
according to the pre-existence of diabetes and its control. 
A study found that markers of inflammation, endothelial 
injury, and coagulation activation were attenuated in the 
patients with stress hyperglycemia without diabetes but 
not in diabetics, suggesting different underlying patho-
physiology. In a large observational study, reduced mor-
tality was observed with blood glucose between 80 and 
140  mg/dl in non-diabetic patients and 110–180  mg/dl 
in diabetic patients (Supplementary References). These 
hypothesis-generating findings are yet to be examined in 
RCTs.
Remaining areas of uncertainty
As indicated above, recent trials have highlighted many 
areas of uncertainty in critical care nutrition. We high-
light selected areas here and in Table 2.
Evaluation of EE and monitoring of nutritional effects 
in different phases of critical illness and across patients 
with different nutritional risks
Indirect calorimetry is considered the gold standard 
in measuring EE in clinical settings [39] and is recom-
mended, when available, by clinical practice guide-
lines, although it is acknowledged that the evidence on 
which this premise is based is limited [5, 40]. Indirect 
calorimetry measurements of EE are generally per-
formed during 1–2  h per day and under controlled 
conditions and therefore do not account for the vari-
ation of EE during 24  h.  Nevertheless, measuring EE 
might have a role in preventing overfeeding. Predictive 
equations are often used instead of direct EE meas-
urement but may over- or underestimate EE and do 
not account for the variation of EE during critical ill-
ness over time [3]. As in clinical practice, most major 
studies including targeted feeding in the design rely 
on these predicted values of EE. A more fundamen-
tal question is whether calories delivered to patients 
during the acute phase of their critical illness should 
match measured or estimated EE despite ongoing 
endogenous nutrient release, which is not suppressed 
by feeding and is unmeasurable [41]. Other important 
questions remain on to how to assess nutritional risk 
and how to to determine which patient groups benefit 
from specific nutritional interventions and which do 
not or experience harm (Table 2)
Method of administration of EN
The approach of continuous feeding has been challenged 
as being unphysiologic [42]. In animal models and in 
healthy volunteers, data suggest that protein synthesis 
is significantly greater after the consumption of a single 
bolus dose of whey protein than when the whey protein 
was given as small-pulsed drinks or as a continuous infu-
sion [42–44]. Intermittent feeding may also have greater 
anabolic response, increased gastric contractility and 
emptying, as well as less diarrhea and better absorption 
owing to slowing of intestinal transit from increased pep-
tide YY release [45, 46]. However, clinical data support-
ing this practice are awaited.
Substrate requirements: proteins and carbohydrates
It remains unclear what constitutes an optimal protein 
“dose” to facilitate recovery of nutritionally high-risk 
patients. Current recommendations  are based on very 
limited evidence. In one trial, a daily intravenous supple-
ment of standard amino acids did not alter the duration 
of renal dysfunction, and functional outcome at 90 days 
was unaffected by the large difference in dose of amino 
acids (0.5–1  kg over 1  week) [47]. In another study, the 
administration of amino acids at either 0.8 or 1.2 g/kg in 
patients receiving PN did not result in a difference in the 
primary endpoint of handgrip at ICU discharge, although 
it resulted in slight improvements in other functional 
outcomes and in nitrogen balance [48]. The interpreta-
tion of these improvements was somewhat complicated 
by the higher mortality (potentially competing with 
weakness) in the patients receiving more amino acids 
[49].
Another issue to consider is whether there is any inter-
relationship between calorie and protein “dose”. There is 
evidence to suggest that if a basal amount of protein is 
provided, varying the percentage of goal calories deliv-
ered may not change outcome. In the PermiT trial [8] 
and other studies [50], restricting calories did not change 
outcome compared to full feeds when protein provision 
was equal between groups. On the other hand, data from 
the International Nutrition Survey 2013 showed that 
achieving at least 80% of prescribed protein intake (but 
not energy intake) was associated with increased survival 
in ICU patients [51]. Another study showed increased 
survival with achievement of protein intake of 1.2  g/kg 
body weight when patients were not overfed with energy 
(more than 110% of measured EE) [52]. An earlier small 
RCT showed that higher protein delivery at 1.4 gm/kg/
day (and reduced calories, 12 kcal/kg) led to better out-
come (reduced SOFA score at 48  h) than lower protein 
doses at 0.76 gm/kg/day (and reduced calories, 14 kcal/
kg) [53].
Not all proteins are equivalent in their ability to stim-
ulate protein synthesis; whey protein (high in leucine) 
may increase muscle synthesis compared to soy or casein 
protein [42]. An RCT in obese older adults showed that 
Table 2 Remaining areas of uncertainty in nutrition of critically ill patients
1. Evaluation of energy expenditure and monitoring of nutritional effects in different phases of critical illness and across patients with different nutri‑
tional risks
 1.1 Does nutrition guided by measuring energy expenditure affect patient outcome as compared to estimated energy expenditure (EE) by predictive 
equations?
 1.2 What is the approach for estimating EE that is associated with improved outcomes?
 1.3 What is the most appropriate energy target expressed as a proportion of (time‑dependent) EE and should energy intake match the EE?
 1.4 How to assess the burden/beneficial effect of feeding on metabolism and cellular integrity in a clinically useful, continuous point of care measure‑
ment monitoring?
 1.5 Is there a role for biomarkers in monitoring feeding?
 1.6 How to identify patients at highest nutritional risk in its acute and chronic components?
 1.7 Does nutrition risk assessment alter the timing of initiation, rate of increase, or ultimate goals of nutrition therapy?
 1.8 What is the role of existing nutritional risk scores including nutritional and non‑nutritional variables (e.g., NRS‑2002 or combination of 
NUTRIC + PANDORA?) [21]
 1.9 How to define and monitor for refeeding syndrome and what is the optimal caloric and protein intake in these patients?
2. Method of administration of enteral and parenteral nutrition
 2.1 What is the optimal timing for initiation of artificial feeding?
 2.2 What is the optimal strategy for management for enteral feeding?
 2.3 How should feeding strategy vary at different stages of critical illness and recovery?
 2.4 What is the effect of continuous feeding vs intermittent feeding on protein synthesis and on patient‑centered outcomes?
 2.5 What is the role of alternative lipid emulsions in PN?
3. Substrate requirements: proteins, carbohydrates, and micronutrients
 3.1 What is optimal protein dose to facilitate recovery of critically ill patients in general and nutritionally high‑risk patients in particular (mortality and 
physical function) and does it need to be combined with some sort of muscle use/exercise?
 3.2 Is there any interrelationship between calorie and protein “dose”?
 3.3 What is the amount of substrate that is actually absorbed in critically ill patients given gut dysfunction and malabsorption?
 3.4 What is the role of whey‑based protein (high in leucine) in muscle synthesis and facilitating recovery from critical illness?
 3.5 What combinations of amino acids are optimal: should they mimic “normal” intake or be aimed at inducing metabolism or supporting host 
defense?
 3.6 What is the role of small peptide vs polymeric formulae in patients at high risk of intolerance?
 3.7 What is the appropriate amount of micronutrients to be provided in ICU patients?
4. Nutrition and functional recovery
 4.1 What is the best way to measure the effect of nutrition on physical recovery outcomes of survivors of ICU?
 4.2 Is there a role for bedside measures to monitor the impact of feeding practices on muscle (such as blood, urine, or muscle imaging) and how to 
correlate these measures with long‑term functional and vital outcomes?
 4.3 What is the effect of combination of ranges of proteins + physical activity + monitoring of muscle mass/function?
5. Management of intestinal and gastric feeding intolerance
 5.1 What is the role of novel pro‑motility agents?
 5.2 Does the acceleration of gastric emptying to increase nutrient delivery to the small intestine during gastric feeding result in improved clinical 
outcomes?
 5.3 What is the association between small bowel feeding and non‑occlusive bowel disease/necrosis?
6. Immune‑modulating nutrition
 6.1 What is the role of glutamine in glutamine‑deficient patients and conditions (like burn‑injured patients)?
 6.2 What is the role of moderate‑dose glutamine in patients receiving exclusive PN after the first week in ICU and in absence of renal or hepatic failure?
 6.3 What is the role of high‑dose IV selenium in cardiac surgery patients?
 6.4 What is the role of high‑dose IV fish oils in inflammatory conditions, like sepsis and cardiac surgery?
 6.5 What is the role of high‑dose zinc supplementation in critically ill adults?
 6.6 What is the role of vitamin D supplementation in critically ill patients?
 6.7 Is there a role of pharmacological agents in promoting retention of muscle mass and improved physical outcomes (e.g., growth hormone, ghrelin 
agonists, anabolic steroids, and others)?
 6.8 Is there a role for arginine/fish oil formula in severe acute pancreatitis?
 6.9 Should pharmaconutrition be used alone or in combination with other EN or PN?
 6.10 What is the effect of timing of immune‑modulating nutrition: pre ICU, early, late etc.?
 6.11 How does the effect of immune‑modulating nutrition relate to the actual immune status?
7. Glucose control
 7.1 Should glucose targets differ by diabetic status? Should glucose targets differ according to previous glycemic control in patients with pre‑existing 
diabetes?
 7.2 What are the prospects for precision glycemic control?
 7.3 Should glucose control differ by feeding strategy and by glucose measurement strategy?
 7.4 What is the role of insulin glargine in glucose control in critically ill patients?
 7.5 What is role for GLP‑1 and its agonists in blood glucose control during critical illness?
 7.6 What is the optimal strategy to control blood glucose with avoidance of hypoglycemia and glycemic fluctuations?
a high whey protein-, leucine-, and vitamin D-enriched 
supplement compared with isocaloric control preserves 
appendicular muscle mass during hypocaloric feeding 
and resistance exercise program [54]. The implications 
for critically ill patients are unknown and require further 
study.
While many different combinations of amino acids are 
theoretically possible, it remains unclear whether these 
combinations should mimic “normal” intake or be aimed 
at inducing metabolism or supporting host defense. In 
contrast to lipids or glucose, an individual amino acid 
given in excess of demands cannot be simply stored and 
needs to be metabolized, thereby consuming other amino 
acids [15, 55].
Protein and functional recovery
Long-term functional recovery of some ICU patients is 
markedly impaired, e.g., patients with severe ARDS only 
achieve 76% of a reference value on 6-min walk test for up 
to 5  years [56]. The relationship between ICU-acquired 
weakness (ICU-AW) and delayed functional recovery 
is only partially established and it is unclear if loss of 
myofiber mass as compared to loss of myofiber integrity 
and quality contributes more to the loss of muscle force 
[15, 57]. Rates of muscle atrophy and changes in muscle 
architecture have been quantified and are associated with 
poor clinical outcomes, although the role of assessment 
of skeletal muscle mass using computed tomography 
imaging and ultrasonography and assessment of fat-free 
Pre-morbid condition Acute illness
Inflammation Rehabilitation
• Energy and protein amount
• Macronutrients
• Antioxidants
• Route of nutrition
• Micronutrients













Fig. 2 How does nutritional support during critical illness affect patient recovery? The effect of nutritional support on recovery may be influenced 
by the amount of calories, protein, other macronutrients, micronutrients, and route of administration. It is probably influenced by premorbid 
nutritional and functional status, by several pathophysiologic processes associated with critical illness, and by the level of rehabilitation. In return, all 
these variables may influence nutritional needs
mass using bioelectrical impedance analysis remain to 
be established [58, 59]. Nevertheless ICU-AW is associ-
ated with a longer hospital stay, decreased likelihood to 
go home after hospital discharge, and reduced long-term 
survival [60].
While it is evident that rehabilitation should play an 
important role, from other areas of research (sports, 
elderly), it is likely that the combination of protein and 
exercise will improve physical performance (Fig.  2) 
[61, 62]. Surprisingly, withholding PN in patients who 
received protocolized physiotherapy and passive or 
active bedcycling reduced the incidence of ICU-AW 
and enhanced recovery in a 600-patient substudy of the 
EPaNIC trial [15]. This underscores the fact that general 
principles that apply in other physiologic conditions may 
not apply to very early ICU nutrition.
While the benefit of early enhanced feeding has long 
been overestimated, the importance of prolonged often 
unnoticed and unintentional underfeeding is under 
addressed, particularly after ICU discharge to the con-
ventional ward [63]. This deserves much more attention, 
as patients in this phase of recovery may be more likely 
to experience benefit by enhanced nutrition possibly in 
combination with physical exercise.
Management of intestinal and gastric feeding intolerance
A meta-analysis of 15 RCTs showed that small intestinal 
feeding compared to gastric feeding improved nutritional 
intake and reduced the incidence of ICU-acquired pneu-
monia but did not affect other clinically important out-
comes [64]. However, the indications for small intestinal 
feeding (when? for whom?) in the ICU remain unclear.
Development of novel motility agents beyond eryth-
romycin and metoclopramide remains an area of active 
investigation. Use of currently available agents is limited 
by the fear of adverse effects and tachyphylaxis as their 
efficacy decreases over time (4–5 days). A novel motilin 
agonist without antibiotic or cardiac effects has recently 
been shown to accelerate gastric emptying in critically ill 
patients (Supplementary References). However, the clini-
cal benefits of gastric emptying acceleration and delivery 
of more nutrition still need to be proven and compared 
to post-pyloric feeding tubes.
Top ten studies/trials to be done in the 
next 10 years
Clinical trial design considerations
Outcomes
It is important that patient-centered outcomes be empha-
sized in clinical phase III trials evaluating nutritional 
interventions; these include mortality, complications 
(including infections), and functional outcomes (includ-
ing the ability to perform prior activities and to return to 
work, muscle strength, walking distance, quality of life). 
Surrogate outcomes such as amount of calories/protein 
delivered, biochemical markers, and glycemic control 
should not be used as primary outcomes for these large-
scale clinical trials.
Study size
Phase III RCTs must be adequately powered and power 
calculations must be performed using realistic event rates 
and expected effect size [65]. The ethics of conducting a 
study doomed to fail need to be questioned.
Time course of the disease and type of critical illness
It may be important to distinguish between acute 
critical illness, subacute critical illness, chronic criti-
cal illness, and the relatively stable postoperative ICU 
patient  (Fig. 2). These different phases of critical illness, 
or specifically the points of “anabolic switch”, are as yet 
undefined. It is possible that, when relevant, nutritional 
support should be individualized on the basis of the 
patient evolution: as the patient improves clinically and 
can start rehabilitation, nutrition support should be 
adapted to the new health state.
Patients
It is of importance to focus on severe critical illness with 
patients who experience organ failure (requiring at least 
invasive mechanical ventilation) and whose outcome 
depends on nutritional support. The nutritional status 
of the patients included in the studies should be detailed 
according to prespecified variables and studies should 
include a priori stratification by nutritional risk. Specific 
types of patients should be identified (e.g., those with 
previous poor nutrition, postoperative, those without 
organ failure and sepsis).
Study design
Interpretation of many critical care nutritional obser-
vational studies is complicated by the presence of many 
confounders and competing outcomes. Adequately pow-
ered RCTs are the best approach to balance measured 
and unmeasured confounders. Many previous nutrition 
trials have been open to bias because they have been 
unblinded.
Top ten trials
There is considerable research being conducted in differ-
ent aspects of nutrition therapy in critically ill patients. 
Table 3 summarizes open RCTs registered on clinicaltri-
als.gov as examples of ongoing work. The panel identi-
fied the following studies as the top 10 trials/studies for 
the next 10 years using the methodology outlined in the 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































suggested candidate topics, then rated each one using a 
grading system (0–4). Potential studies were ranked on 
the basis of average score. The following received the 
highest priory scores.
 1. To study the effects of high compared to low protein 
dose combined with standardized active and passive 
mobilization during the acute phase of critical illness 
on mortality and recovery of severely ill patients.
Table 4 Selecting the top 10 trials in critical care nutrition and metabolism
Members of the panel suggested candidate topics that underwent several rounds of discussion. Finally, the panel reached a list of 21 topics. Members of the panel 
rated each one of the topics using a grading system: 4 top priority, 3 high priority, 2 intermediate priority, 1 low priority, and 0 not a priority. For each candidate topic 
we calculate the average score given by the panel. The table shows the 21 topics with the average score in descending order. After finalizing the survey, the panel 
reviewed the top 10 topics. The panel agreed on merging topics 5 and 8 and on deleting item 6 as it was covered by earlier items. As such items 11 and 12 were 
moved up in rank
Topic # Candidate research topic Average score
1 Effects of high vs low protein dose combined with standardized active and passive mobilization during the acute phase 
of critical illness on (mortality and) recovery (physical function, ICU length of stay) of severely ill patients (treated with 
mechanical ventilation and vasoactive drugs during the acute phase). The study should include a priori stratification by 
nutritional risk
3.71
2 Effects of high vs low protein dose combined with standardized active and passive mobilization post‑acute phase of critical 
illness on (mortality and) recovery (physical function, ICU length of stay, MV duration) of severely ill patients (treated with 
mechanical ventilation and vasoactive drug during the acute phase). The study should include a priori stratification by 
nutritional risk
2.93
3 Comparative study of different nutritional assessment tools to identify the best tool that differentiates the response to 
caloric and protein intake
2.93
4 Effects of permissive underfeeding (calories) with and without high‑dose protein supplementation in critically ill obese on 
(mortality and) physical function
2.57
5 Effects of continuous versus intermittent (infuse 20–30 min, off 90 min, repeat q 2 h) feeding on mechanistic markers as a 
prerequisite to a larger RCT
2.36
6 Best feeding strategy for sepsis patients with respect to calories and proteins 2.36
7 Effects of high vs low energy dose with standardized active and passive mobilization post‑acute phase of critical illness on 
(mortality and) recovery (physical function, ICU length of stay) of severely ill patients (treated with mechanical ventilation 
and vasoactive drug during the acute phase)
2.29
8 Effects of continuous versus intermittent (infuse 20–30 min, off 90 min, repeat q 2 h) feeding on (mortality and) physical 
function
2.21
9 What bedside assessment of muscle mass can accurately identify low muscle mass, be used to monitor nutrition success, 
and predict for function recovery?
2.14
10 A pragmatic RCT of standardized parenteral supplementation of daily requirements of all micronutrients until full EN is 
achieved in critically ill patients on mortality and/or functional recovery
2.14
11 RCT evaluating the effects of prokinetic use on the recovery of critically ill patients with persistent intolerance to EN 2.00
12 Effects of high vs low energy dose with standardized active and passive mobilization during the acute phase of critical illness 
on (mortality and) recovery (physical function, ICU length of stay) of severely ill patients (treated with mechanical ventila‑
tion and vasoactive drug during the acute phase)
1.93
13 Effects of stepwise increases in caloric provision during the first week on the complication rate and physical function 1.93
14 Whey‑based protein (high in leucine) (with or without some form of exercise) compared to soy or casein‑based protein on 
mortality and physical function
1.86
15 Revisiting liberal versus strict glucose control in a setting of tolerated early hypocaloric feeding, strict separation of the 
glucose levels obtained in the liberal and strict arm in non‑diabetic and diabetic critically ill patients on mortality, organ 
function, and functional status
1.79
16 Effects of permissive underfeeding (calories) with high‑dose protein supplementation in critically ill diabetic patients on 
(mortality and) physical function
1.71
17 Nutrition and physical activity guided by muscle mass assessment on (mortality and) long‑term physical function 1.50
18 RCT of small peptide vs polymeric in patients at high risk of intolerance on (mortality and) recovery (physical function, ICU 
length of stay) and nutritional adequacy (intake)
1.36
19 Use of resolvins and/or protectins in critically ill patients. The main outcomes are mortality and physical function 1.29
20 The effect of GLP‑1 and its agonists in hyperglycemic critically ill patients on mortality on mortality, organ function, and 
functional status
1.14
21 The effect of insulin glargine in hyperglycemic critically ill patients on mortality, organ function, and functional status 1.07
 2. To study the effects of high compared to low protein 
dose combined with standardized active and passive 
mobilization during the post-acute phase of critical ill-
ness on mortality and recovery of severely ill patients.
 3. To determine which patient groups benefit from 
specific nutritional interventions and which do not 
or experience harm. Such determination requires 
development and/or validation of clinical and labo-
ratory nutritional assessment tools, with validation 
being best done in RCTs.
 4. To examine the effects of permissive underfeeding 
(caloric restriction) with and without high-dose pro-
tein supplementation in critically ill obese on mor-
tality and physical function.
 5. To study the effects of continuous versus intermit-
tent EN on mechanistic markers in a phase II trial to 
inform a phase III RCT with mortality and physical 
function being the main outcomes.
 6. To study the effects of high compared to low energy 
dose with standardized active and passive mobiliza-
tion post-acute phase of critical illness on mortality 
and recovery of severely ill patients.
 7. To determine which bedside assessment of muscle 
mass can accurately identify low muscle mass, be 
used to monitor nutrition success, and predict func-
tional recovery.
 8. To perform a pragmatic RCT of standardized par-
enteral supplementation of daily requirements of all 
micronutrients until full EN is achieved in critically 
ill patients on mortality and/or functional recovery.
 9. To evaluate the effects of prokinetic use on the 
recovery of critically ill patients with persistent intol-
erance to EN.
 10. To study the effects of high vs low energy dose with 
standardized active and passive mobilization during 
the acute phase of critical illness on mortality and 
recovery of severely ill patients.
In conclusion, recent trials have answered impor-
tant questions but also highlighted or revealed several 
uncertainties in many aspects of critical care nutrition 
and metabolism. We ranked the top 10 studies for the 
next 10  years, with the prospect that different nutri-
tional interventions targeted to the appropriate patient 
population will be examined for their effect on facili-
tating recovery and improving survival in adequately 
powered and properly designed studies, probably in 
conjunction with mobilization. Undoubtedly, the next 
10 years are likely to be an exciting era for nutrition and 
metabolism.
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